162 related articles for article (PubMed ID: 26027565)
1. Intratumoral Pharmacokinetics: Challenges to Nanobiomaterials.
Al-Abd AM; Al-Abbasi FA; Torchilin VP
Curr Pharm Des; 2015; 21(22):3208-14. PubMed ID: 26027565
[TBL] [Abstract][Full Text] [Related]
2. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles.
Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y
J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106
[TBL] [Abstract][Full Text] [Related]
3. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.
Ernsting MJ; Murakami M; Roy A; Li SD
J Control Release; 2013 Dec; 172(3):782-94. PubMed ID: 24075927
[TBL] [Abstract][Full Text] [Related]
4. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
Durymanov MO; Rosenkranz AA; Sobolev AS
Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors.
Al-Abd AM; Aljehani ZK; Gazzaz RW; Fakhri SH; Jabbad AH; Alahdal AM; Torchilin VP
J Control Release; 2015 Dec; 219():269-277. PubMed ID: 26342660
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: a systematic review.
Abdifetah O; Na-Bangchang K
Int J Nanomedicine; 2019; 14():5659-5677. PubMed ID: 31632004
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics.
Jin SE; Jin HE; Hong SS
Biomed Res Int; 2014; 2014():814208. PubMed ID: 24672796
[TBL] [Abstract][Full Text] [Related]
8. Advances in stimuli responsive nanobiomaterials for cancer therapy.
Sampathkumar K; Arulkumar S; Ramalingam M
J Biomed Nanotechnol; 2014 Mar; 10(3):367-82. PubMed ID: 24730233
[TBL] [Abstract][Full Text] [Related]
9. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
Nakamura H; Fang J; Maeda H
Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
[TBL] [Abstract][Full Text] [Related]
10. Drug penetration in solid tumours.
Minchinton AI; Tannock IF
Nat Rev Cancer; 2006 Aug; 6(8):583-92. PubMed ID: 16862189
[TBL] [Abstract][Full Text] [Related]
11. Nanocarriers to solid tumors: considerations on tumor penetration and exposure of tumor cells to therapeutic agents.
Bhagat M; Halligan S; Sofou S
Curr Pharm Biotechnol; 2012 Jun; 13(7):1306-16. PubMed ID: 22201591
[TBL] [Abstract][Full Text] [Related]
12. Biocompatibility and biodistribution of suberoylanilide hydroxamic acid loaded poly (DL-lactide-co-glycolide) nanoparticles for targeted drug delivery in cancer.
Sankar R; Ravikumar V
Biomed Pharmacother; 2014 Sep; 68(7):865-71. PubMed ID: 25107842
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle approaches to combating drug resistance.
Moon JH; Moxley JW; Zhang P; Cui H
Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
[TBL] [Abstract][Full Text] [Related]
14. Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs.
Joanitti GA; Ganassin R; Rodrigues MC; Figueiro Longo JP; Jiang CS; Gu J; Leal Pinto SM; Almeida Dos Santos MF; de Azevedo RB; Muehlmann LA
Mini Rev Med Chem; 2017; 17(3):224-236. PubMed ID: 27739361
[TBL] [Abstract][Full Text] [Related]
15. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
16. Emerging potential of stimulus-responsive nanosized anticancer drug delivery systems for systemic applications.
Ruttala HB; Ramasamy T; Madeshwaran T; Hiep TT; Kandasamy U; Oh KT; Choi HG; Yong CS; Kim JO
Arch Pharm Res; 2018 Feb; 41(2):111-129. PubMed ID: 29214601
[TBL] [Abstract][Full Text] [Related]
17. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin S; Nehoff H; Greish K
J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
[TBL] [Abstract][Full Text] [Related]
18. Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening.
Millard M; Yakavets I; Zorin V; Kulmukhamedova A; Marchal S; Bezdetnaya L
Int J Nanomedicine; 2017; 12():7993-8007. PubMed ID: 29184400
[TBL] [Abstract][Full Text] [Related]
19. Physical oncology: New targets for nanomedicine.
Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modeling analysis of intratumoral disposition of anticancer agents and drug delivery systems.
Popilski H; Stepensky D
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):767-84. PubMed ID: 25813659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
